STOCK TITAN

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company based in Tübingen, Germany, is set to report its fourth quarter and full-year 2022 financial results on April 25, 2023. The company will also offer business updates during a conference call at 3 p.m. CET / 9 a.m. EST. Interested parties can join via U.S. Toll-Free number or through international dial-in options. A live webcast will also be available on the CureVac website. This announcement follows CureVac's notable history in developing mRNA technology, including a partnership with GSK for vaccine development. With over 20 years of expertise, CureVac continues to build a robust clinical pipeline targeting various diseases.

Positive
  • CureVac is releasing fourth quarter and full-year 2022 financial results, which may reflect business performance.
  • The company has a collaboration with GSK to develop new mRNA-based vaccines, potentially enhancing its market position.
Negative
  • None.

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2022 on Tuesday, April 25, 2023. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.

Conference call and webcast details

Dial-in numbers to participate in the conference call:

U.S. Toll-Free: +1-877-407-0989

International: +1-201-389-0921

Germany: 0800 182 0040 (landline access), 0800 184 4713 (cell phone access)

The live webcast link can be accessed via the newsroom/events section of the CureVac website at https://www.curevac.com/en/newsroom/events/

Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available at this website after the event.

About CureVac

CureVac (Nasdaq:CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

CureVac Investor Relations Contact

Dr. Sarah Fakih, Vice President Corporate Communications, and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

CureVac Media Contact

Bettina Jödicke-Braas, Manager Communications
CureVac, Tübingen, Germany
T: 49 7071 9883-1087
bettina.joedicke-braas@curevac.com

Forward-Looking Statements CureVac

This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include statements regarding the completion, size, and terms of the proposed public offering. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

SOURCE: CureVac



View source version on accesswire.com:
https://www.accesswire.com/749775/CureVac-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Updates-on-April-25-2023

FAQ

When will CureVac release its 2022 financial results?

CureVac will report its financial results for the fourth quarter and full-year 2022 on April 25, 2023.

What time is the CureVac conference call scheduled for?

The conference call is scheduled for 3 p.m. CET / 9 a.m. EST on April 25, 2023.

How can I access the CureVac conference call?

The conference call can be accessed via U.S. Toll-Free and international dial-in numbers, as well as through a live webcast on the CureVac website.

What technology does CureVac specialize in?

CureVac specializes in messenger RNA (mRNA) technology for developing transformative medicines.

CureVac N.V. Ordinary Shares

NASDAQ:CVAC

CVAC Rankings

CVAC Latest News

CVAC Stock Data

671.89M
122.80M
45.26%
18.87%
1.97%
Biotechnology
Healthcare
Link
United States of America
Tübingen